Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey

Autoři: Andrea De Luca aff001;  Patrizio Pezzotti aff003;  Charles Boucher aff004;  Matthias Döring aff005;  Francesca Incardona aff006;  Rolf Kaiser aff008;  Thomas Lengauer aff005;  Nico Pfeifer aff005;  Eugen Schülter aff008;  Anne-Mieke Vandamme aff010;  Maurizio Zazzi aff001;  Anna Maria Geretti aff012
Působiště autorů: Department of Medical Biotechnologies, University of Siena, Siena, Italy aff001;  Unità Operativa Complessa Malattie Infettive, Azienda Ospedaliera Universitaria Senese, Siena, Italy aff002;  Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy aff003;  Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands aff004;  Max Planck Institute for Informatics, Saarland Informatics Campus, Saarbrücken, Germany aff005;  EuResist Network, Rome, Italy aff006;  InformaPRO, Rome, Italy aff007;  Institute of Virology, University of Cologne, Cologne, Germany aff008;  Department of Computer Science, University of Tübingen, Tübingen, Germany aff009;  Department of Microbiology, Immunology and Transplantation, KU Leuven, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium aff010;  Center for Global Health and Tropical Medicine, Unidade de Microbiologia, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal aff011;  Institute of Infection and Global Health, University of Liverpool, Liverpool, England, United Kingdom aff012
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225381



The study aimed to survey maraviroc use and assess effectiveness and durability of maraviroc-containing antiretroviral treatment (ART) in routine practice across Europe.


Data were retrieved from 26 cohorts in 8 countries comprising adults who started maraviroc in 2005–2016 and had ≥1 follow-up visit. Available V3 sequences were re-analysed centrally for tropism determination by geno2pheno[coreceptor]. Treatment failure (TF) was defined as either virological failure (viral load >50 copies/mL) or maraviroc discontinuation for any reason over 48 weeks. Predictors of TF were explored by logistic regression analysis. Time to maraviroc discontinuation was estimated by Kaplan-Meier survival analysis.


At maraviroc initiation (baseline), among 1,381 patients, 67.1% had experienced ≥3 ART classes and 45.6% had a viral load <50 copies/mL. Maraviroc was occasionally added to the existing regimen as a single agent (7.3%) but it was more commonly introduced alongside other new agents, and was often (70.4%) used with protease inhibitors. Accompanying drugs comprised 1 (40.2%), 2 (48.6%) or ≥3 (11.2%) ART classes. Among 1,273 patients with available tropism data, 17.6% showed non-R5 virus. Non-standard maraviroc use also comprised reported once daily dosing (20.0%) and a total daily dose of 150mg (12.1%). Over 48 weeks, 41.4% of patients met the definition of TF, although the 1-year estimated retention on maraviroc was 82.1% (95% confidence interval 79.9–84.2). Among 1,010 subjects on maraviroc at week 48, the viral load was >50 copies/mL in 19.9% and >200 copies/mL in 10.7%. Independent predictors of TF comprised a low nadir CD4 count, a detectable baseline viral load, previous PI experience, non-R5 tropism, having ≥3 active drugs in the accompanying regimen, and a more recent calendar year of maraviroc initiation.


This study reports on the largest observation cohort of patients who started maraviroc across 8 European countries. In this overall highly treatment-experienced population, with a small but appreciable subset that received maraviroc outside of standard treatment guidelines, maraviroc was safe and reasonably effective, with relatively low rates of discontinuation over 48 weeks and only 2 cases of serum transaminase elevations reported as reasons for discontinuation.

Klíčová slova:

Antimicrobial resistance – Antiretrovirals – Drug therapy – Europe – HIV-1 – Viral load – Viral tropism


1. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol. 2007 Dec;25(12):1407–10. doi: 10.1038/nbt1371 18066037.

2. Harrigan PR, Geretti AM. Genotypic tropism testing: evidence-based or leap of faith? AIDS. 2011 Jan 14;25(2):257–64. doi: 10.1097/QAD.0b013e32834113f9 21099667

3. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Sauné K et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS. 2008 Sep 12;22(14):F11–6. doi: 10.1097/QAD.0b013e32830ebcd4 18753930.

4. Seclén E, Garrido C, González Mdel M, González-Lahoz J, de Mendoza C, Soriano V et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother. 2010 Jul;65(7):1486–92. doi: 10.1093/jac/dkq137 Epub 2010 Apr 28. 20427374.

5. Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F, Meini G et al. Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology. 2010 Jun 30;7:56. doi: 10.1186/1742-4690-7-56 20591141; PubMed Central PMCID: PMC2907304.

6. Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol. 2007 Feb;45(2):279–84. Epub 2006 Nov 22. doi: 10.1128/JCM.01118-06 17122004; PubMed Central PMCID: PMC1829003.

7. Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K et al. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. J Antimicrob Chemother. 2011 Feb;66(2):265–72. doi: 10.1093/jac/dkq458 Epub 2010 Dec 31 21196489

8. Sierra-Madero J, Di Perri G, Wood R, Saag M, Frank I, Craig C et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials. 2010 May-Jun;11(3):125–32. doi: 10.1310/hct1103-125 20736149.

9. Cooper DA, Heera J, Ive P, Botes M, Dejesus E, Burnside R et al. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. AIDS. 2014 Mar 13;28(5):717–25. doi: 10.1097/QAD.0000000000000131 24983542; PubMed Central PMCID: PMC3940293.

10. Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558–64. doi: 10.1097/QAI.0b013e3181ee3d82 20703158; PubMed Central PMCID: PMC3321258.

11. Nozza S, Galli L, Visco F, Soria A, Canducci F, Salpietro S et al. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS. 2010 Mar 27;24(6):924–8. doi: 10.1097/QAD.0b013e3283372d76 20154578.

12. Lazzarin A, Reynes J, Molina JM, Valluri S, Mukwaya G, Heera J et al. The maraviroc expanded access program—safety and efficacy data from an open-label study. HIV Clin Trials. 2015 Jan-Feb;16(1):10–21. doi: 10.1179/1528433614Z.0000000002 Epub 2015 Jan 23. 25777185.

13. Waters L, Jackson A, Else L, Rockwood N, Newell S, Back D et al. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy. Antivir Ther. 2015;20(2):157–63. doi: 10.3851/IMP2817 Epub 2014 Jun 25. 24963558.

14. Saumoy M, Llibre JM, Terrón A, Knobel H, Arribas JR, Domingo P et al. Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. AIDS Res Hum Retroviruses. 2017 Jan;33(1):29–32. doi: 10.1089/AID.2015.0386 Epub 2016 Dec 20. 27250802.

15. Blanco JR, Arroyo-Manzano D, Rojas-Liévano JF, Crespo M, Bravo I, Pasquau J et al. The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age. AIDS Res Hum Retroviruses. 2015 Sep;31(9):893–7. doi: 10.1089/AID.2015.0016 Epub 2015 Jun 15. 26059859.

16. Llibre JM, Rivero A, Rojas JF, Garcia Del Toro M, Herrero C, Arroyo D et al. Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. Antiviral Res. 2015 Aug;120:79–84. doi: 10.1016/j.antiviral.2015.05.001 Epub 2015 May 12. 25977241.

17. Macías J, Recio E, Márquez M, García C, Jiménez P, Merino D et al. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting. HIV Med. 2014 Aug;15(7):417–24. doi: 10.1111/hiv.12129 Epub 2014 Feb 24. 24580801.

18. Bonjoch A, Pou C, Pérez-Álvarez N, Bellido R, Casadellà M, Puig J et al. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. J Antimicrob Chemother. 2013 Jun;68(6):1382–7. doi: 10.1093/jac/dks539 Epub 2013 Jan 25. 23354282.

19. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A et al.; European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis. 2011 May;11(5):394–407. doi: 10.1016/S1473-3099(10)70319-4 Epub 2011 Mar 21. Review. 21429803.

20. Schapiro JM, Boucher CAB, Kuritzkes DR, van de Vijver DA, Llibre JM, et al. Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antiviral Therapy 2011; 16:395–404 doi: 10.3851/IMP1759 21555822

21. Ghidei L, Simone MJ, Salow MJ, Zimmerman KM, Paquin AM, Skarf LM et al. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging. 2013 Oct;30(10):809–19. doi: 10.1007/s40266-013-0107-7 Review. 23959913; PubMed Central PMCID: PMC3844933.

22. Bocket L, Peytavin G, Alidjinou EK, Ajana F, Choisy P, Lê M et al. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients. J Antimicrob Chemother. 2016 Sep;71(9):2651–3. doi: 10.1093/jac/dkw167 Epub 2016 May 27. 27234463.

23. Santos JR, Blanco JL, Masiá M, Gutiérrez F, Pérez-Elías MJ, Iribarren JA et al.; Integrase Resistance Study Group in Spain (INI-VAIN Study Group); Integrase Resistance Study Group in Spain INI-VAIN Study Group. Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. J Antimicrob Chemother. 2015 Nov;70(11):3087–95. doi: 10.1093/jac/dkv205 Epub 2015 Jul 30. 26490727.

24. Gutmann C, Cusini A, Günthard HF, Fux C, Hirschel B, Decosterd LA et al; Swiss HIV Cohort Study (SHCS). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010 Sep 24;24(15):2347–54. doi: 10.1097/QAD.0b013e32833db9a1 20802298.

25. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46:1617–1623. doi: 10.1086/587660 18419499

26. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis. 2011 Oct;53(7):732–42. doi: 10.1093/cid/cir493 21890778.

27. Stockdale AJ, Saunders MJ, Boyd MA, Bonnett LJ, Johnston V, Wandeler G et al. Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018 Jun 1;66(12):1846–1857. doi: 10.1093/cid/cix1108 29272346; PubMed Central PMCID: PMC5982734.

28. Cillo AR, Hilldorfer BB, Lalama CM, McKinnon JE, Coombs RW, Tenorio AR et al. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. AIDS. 2015 Oct 23;29(16):2121–9. doi: 10.1097/QAD.0000000000000810 26544577; PubMed Central PMCID: PMC4638139.

29. Okoli C, Siccardi M, Thomas-William S, Dufty N, Khonyongwa K, Ainsworth J et al. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J Antimicrob Chemother. 2012 Mar;67(3):671–4. doi: 10.1093/jac/dkr493 Epub 2011 Dec 15. 22174038.

30. Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J et al.; A4001029 Study Group. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis. 2009 Jun 1;199(11):1638–47. doi: 10.1086/598965 19432546.

31. van Lelyveld SF, Drylewicz J, Krikke M, Veel EM, Otto SA, Richter C et al.; MIRS study group. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. PLoS One. 2015 Jul 24;10(7):e0132430. doi: 10.1371/journal.pone.0132430 eCollection 2015. 26208341; PubMed Central PMCID: PMC4514679.

32. Bader J, Däumer M, Schöni-Affolter F, Böni J, Gorgievski-Hrisoho M, Martinetti G et al.; Swiss HIV Cohort Study. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1. Clin Infect Dis. 2017 Feb 1;64(3):295–300. doi: 10.1093/cid/ciw737 Epub 2016 Nov 12. 27838645.

33. Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15;206(4):534–42. doi: 10.1093/infdis/jis376 Epub 2012 Jun 27. 22740718; PubMed Central PMCID: PMC3491731.

34. Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D'Amore C et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation. 2013 May 28;127(21):2114–24. doi: 10.1161/CIRCULATIONAHA.113.001278 Epub 2013 Apr 30. 23633271.

35. Rossetti B, Gagliardini R, Sterrantino G et al. The effect of switching to Darunavir/r + Maraviroc dual therapy in virologically suppressed patients on the progression of liver fibrosis: findings from a randomized study. 9th Italian Conference on AIDS and Antiviral Research, Siena, Italy, June 12–14 2017, P6

Článek vyšel v časopise


2019 Číslo 11